BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 23650219)

  • 1. Treatment with topotecan plus cyclophosphamide in children with first relapse of neuroblastoma.
    Ashraf K; Shaikh F; Gibson P; Baruchel S; Irwin MS
    Pediatr Blood Cancer; 2013 Oct; 60(10):1636-41. PubMed ID: 23650219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study.
    London WB; Frantz CN; Campbell LA; Seeger RC; Brumback BA; Cohn SL; Matthay KK; Castleberry RP; Diller L
    J Clin Oncol; 2010 Aug; 28(24):3808-15. PubMed ID: 20660830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.
    Hunold A; Weddeling N; Paulussen M; Ranft A; Liebscher C; Jürgens H
    Pediatr Blood Cancer; 2006 Nov; 47(6):795-800. PubMed ID: 16411206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclophosphamide and topotecan as first-line salvage therapy in patients with relapsed ewing sarcoma at a single institution.
    Farhat R; Raad R; Khoury NJ; Feghaly J; Eid T; Muwakkit S; Abboud M; El-Solh H; Saab R
    J Pediatr Hematol Oncol; 2013 Jul; 35(5):356-60. PubMed ID: 23042020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serial intense chemotherapy combining topotecan, etoposide, carboplatin and cyclophosphamide (TECC) followed by autologous hematopoietic stem cell support in patients with high risk soft tissue sarcoma (STS).
    Bernbeck B; Bahci S; Meisel R; Troeger A; Schönberger S; Laws HJ; Kramm C; Wessalowski R; Koscielniak E; Dilloo D; Göbel U
    Klin Padiatr; 2007; 219(6):318-22. PubMed ID: 18050041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of relapsed Wilms' tumor with high-dose therapy and autologous hematopoietic stem-cell rescue: the experience at Children's Memorial Hospital.
    Campbell AD; Cohn SL; Reynolds M; Seshadri R; Morgan E; Geissler G; Rademaker A; Marymount M; Kalapurakal J; Haut PR; Duerst R; Kletzel M
    J Clin Oncol; 2004 Jul; 22(14):2885-90. PubMed ID: 15254057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma?
    Al-Faris N; Al Harbi T; Goia C; Pappo A; Doyle J; Gassas A
    Pediatr Blood Cancer; 2007 Aug; 49(2):190-5. PubMed ID: 17262797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update.
    George RE; Li S; Medeiros-Nancarrow C; Neuberg D; Marcus K; Shamberger RC; Pulsipher M; Grupp SA; Diller L
    J Clin Oncol; 2006 Jun; 24(18):2891-6. PubMed ID: 16782928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topotecan, thiotepa, and carboplatin for neuroblastoma: failure to prevent relapse in the central nervous system.
    Kushner BH; Kramer K; Modak S; Kernan NA; Reich LM; Danis K; Cheung NK
    Bone Marrow Transplant; 2006 Feb; 37(3):271-6. PubMed ID: 16400336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: pharmacological rationale and clinical response.
    Donfrancesco A; De Ioris MA; McDowell HP; De Pasquale MD; Ilari I; Jenkner A; Castellano A; Cialfi S; De Laurentis C; Dominici C
    Pediatr Blood Cancer; 2010 Jan; 54(1):55-61. PubMed ID: 19821523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults.
    Kushner BH; Cheung NK; Kramer K; Dunkel IJ; Calleja E; Boulad F
    Bone Marrow Transplant; 2001 Sep; 28(6):551-6. PubMed ID: 11607767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a pediatric oncology group study.
    Kretschmar CS; Kletzel M; Murray K; Thorner P; Joshi V; Marcus R; Smith EI; London WB; Castleberry R
    J Clin Oncol; 2004 Oct; 22(20):4119-26. PubMed ID: 15483021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk neuroblastoma patients.
    Molina B; Alonso L; Gonzalez-Vicent M; Andion M; Hernandez C; Lassaletta A; Cormenzana M; Lopez-Ibor B; Villa M; Molina J; Diaz MA
    Pediatr Hematol Oncol; 2011 Mar; 28(2):115-23. PubMed ID: 21299340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study.
    Di Giannatale A; Dias-Gastellier N; Devos A; Mc Hugh K; Boubaker A; Courbon F; Verschuur A; Ducassoul S; Malekzadeh K; Casanova M; Amoroso L; Chastagner P; Zwaan CM; Munzer C; Aerts I; Landman-Parker J; Riccardi R; Le Deley MC; Geoerger B; Rubie H
    Eur J Cancer; 2014 Jan; 50(1):170-7. PubMed ID: 24021349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
    Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
    Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloablative chemotherapy with autologous peripheral blood stem cell transplantation in patients with poor-prognosis solid tumors - Bulgarian experience.
    Avramova B; Jordanova M; Michailov G; Konstantinov D; Christosova I; Bobev D
    J BUON; 2006; 11(4):433-8. PubMed ID: 17309174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer.
    Donato ML; Gershenson DM; Wharton JT; Ippoliti CM; Aleman AS; Bodurka-Bevers D; Bevers MW; Burke TW; Levenback CF; Wolf JK; Freedman RS; Bast RC; Gajewski JL; Champlin RE
    Gynecol Oncol; 2001 Sep; 82(3):420-6. PubMed ID: 11520135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topotecan plus cyclophosphamide as maintenance chemotherapy for children with high-risk neuroblastoma in complete remission: short-term curative effects and toxicity.
    Feng C; Tang S; Wang J; Liu Y; Yang G
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Aug; 33(8):1107-10. PubMed ID: 23996746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A modified protocol with vincristine, topotecan, and cyclophosphamide for recurrent/progressive ewing sarcoma family tumors.
    Kebudi R; Cakir FB; Gorgun O; Agaoglu FY; Darendeliler E
    Pediatr Hematol Oncol; 2013 Apr; 30(3):170-7. PubMed ID: 23484903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.